Metonitazene
Chemical compound (analgesic drug)
From Wikipedia, the free encyclopedia
Metonitazene is an analgesic compound related to etonitazene,[2][3] which was first reported in 1957,[4] and has been shown to have approximately 100 times the potency of morphine by central routes of administration,[5][6] but if used orally it has been shown to have approximately 10 times the potency of morphine.[7]
- BR: Class F1 (Prohibited narcotics)
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class A
- US: Schedule I
- Illegal in Sweden[1]
| |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H26N4O3 |
| Molar mass | 382.464 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Its effects are similar to other opioids such as fentanyl and heroin, including analgesia, euphoria, and sleepiness.[7][8] Adverse effects include vomiting, and respiratory depression that can potentially be fatal.[9] Because of high dependency potential and dangerous adverse effects it has never been introduced into pharmacotherapy. It is instead commonly used in the illicit manufacture of counterfeit oxycodone opioid pills.[10]
Legal status
In the United States, metonitazene is a Schedule I controlled substance under the Controlled Substances Act.
Metonitazene is not controlled under the 1971 Convention on Psychotropic Substances; however, in many countries possession or intent to sell for human consumption might be prosecuted under several analog acts.
Metonitazene became a Class A drug in the UK on 20th March 2024.